Med-Zenith Secures Investment from GAGE Capital to Advance High-End Cardiovascular Devices and Consumables, with WinX Capital as Exclusive Financial Advisor

VCBeat (WeChat: vcbeat) learned that recently, Beijing Med-Zenith Medical Scientific Corporation Limited (hereinafter referred to as "Med-Zenith") has introducedThe new investor is Beijing Janggen (GAGE) Capital Management Co., Ltd. (hereinafter referred to as "Janggen Capital"). WinX Capital served as the exclusive financial advisor for this transaction.

Med-Zenith

Med-Zenith is an innovative enterprise that develops high-quality equipment and high-end consumables for cardiovascular diseases and provides comprehensive treatment solutions. With a registered capital of 270 million yuan, it is a national high-tech enterprise, a "Little Giant" enterprise specializing in niche industries under the Ministry of Industry and Information Technology, a Beijing Intellectual Property Demonstration Unit, and a Zhongguancun Gazelle Enterprise. It is the only high-value medical consumables manufacturing enterprise located within a bonded area in China.

Among the approved products on the market, including E-Clip, which is currently the first in China to target 20 million atrial fibrillation patients and 5 million cardiogenic stroke patients for left atrial appendage closure.^®"Left Atrial Appendage Closure System", a nationally innovative product prioritized for review through the green channel; Pul-Stent, the globally exclusive product launched in 2020.^®Pulmonary artery stents are a nationally "clinically urgent" priority approval product, serving millions of patients with pulmonary artery stenosis worldwide. The radiofrequency ablation series for atrial fibrillation treatment has broken the monopoly of imported products, achieving domestic substitution.

Currently, several innovative products have entered clinical research, such as: the interventional pulmonary artery valve (PT-Valve).^®) is a national "13th Five-Year Plan" project, currently undergoing pre-market clinical trials, with over 140 implants completed and follow-up results showing promising outcomes. It is the only formal registered clinical trial in China to have received pre-clinical approval from the National Medical Products Administration, with an expected product launch in 2024.

About This TransactionMed-Zenith TeamMed-Zenith expressed deep gratitude for the support and trust from Janggen Capital, with whom we will jointly integrate resources to empower Med-Zenith. This collaboration allows us to accelerate the development of high-quality cardiovascular disease devices and premium medical consumables. At the same time, Med-Zenith is honored to have the opportunity to contribute our team's extensive industry experience and innovative technical products to the rapidly growing healthcare industry. In the future, we will continue to innovate medical concepts, save patients' lives, and actively create sustainable long-term value for our shareholders.

The exclusive financial advisor for this transaction, VCBeat CapitalVCBeat: WinX Capital is delighted to assist Med-Zenith in bringing on board a brand-name investment institution as a new shareholder. Med-Zenith is a high-quality cardiovascular platform in the primary market with a unique perspective and long-term value. The company boasts exceptional innovation capabilities, holding several industry-first and pioneering key product pipelines, providing comprehensive overall solutions for a wide range of cardiovascular disease patients. Centered on patients and clinical needs, the company has comprehensively laid out its operations in valves, congenital heart diseases, atrial fibrillation, and stroke; developing a product pipeline that combines minimally invasive surgery and interventional approaches. The company gathers top teams from home and abroad, based in China while planning globally. We look forward to the company seizing opportunities and achieving leapfrog development with the support of both new and existing investors.

Beijing Janggen Capital Management Co., Ltd. ("Janggen Capital" for short) was established in 2012 as a private equity investment institution focusing on equity investment, mergers and acquisitions, and other businesses. Guided by national strategic needs, Janggen Capital concentrates on investing in strategic emerging industries, targeting projects that break through "bottleneck" technologies. The company pays close attention to fields such as healthcare, advanced manufacturing and semiconductors, big data and artificial intelligence, and new energy. Janggen Capital is committed to leveraging an international perspective to connect with high-quality global resources, providing diversified financial service solutions, and building an investment company with global competitiveness.

Jianggen Capital has high expectations for Med-Zenith, a powerful company leading innovation and transformation in China's medical device industry. Jianggen Capital will leverage financial strength to support the company’s industrial upgrading, create long-term value, and promote positive and diversified social development. Jianggen Capital will continue to explore cooperation potential with Med-Zenith, connect resources to empower partners, and jointly create real and profound value.